BETA:NSE Beta Drugs Ltd.

INR 1,197.80 0.00 0
Icon

Beta Drugs Ltd. (BETA:NSE) Stock Analysis and Price Targets

COMMON STOCK | Others | NSE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 1,197.80

0.00 (0.00)%

N/A

5.20K

N/A

N/A

Icon

BETA:NSE

Beta Drugs Ltd. (INR)
COMMON STOCK | NSE
INR 1,197.80
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

N/A

N/A

INR 1,197.80

Beta Drugs Ltd. (BETA:NSE) Stock Forecast

INR 1,600.00
(+33.58%)

Based on the Beta Drugs Ltd. stock forecast from 1 analysts, the average analyst target price for Beta Drugs Ltd. is INR 1,600.00 over the next 12 months. Beta Drugs Ltd.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Beta Drugs Ltd. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Beta Drugs Ltd.’s stock price was INR 1,197.80. Beta Drugs Ltd.’s stock price has changed by -1.24% over the past week, -2.07% over the past month and 0% over the last year.

No recent analyst target price found for Beta Drugs Ltd.
No recent average analyst rating found for Beta Drugs Ltd.

Company Overview Beta Drugs Ltd.

Address:

N/A

N/A

N/A

N/A

INR

India

Adjusted Closing Price for Beta Drugs Ltd. (BETA:NSE)

Loading...

Unadjusted Closing Price for Beta Drugs Ltd. (BETA:NSE)

Loading...

Share Trading Volume for Beta Drugs Ltd. Shares

Loading...

Compare Performance of Beta Drugs Ltd. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BETA:NSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Beta Drugs Ltd. (Sector: Others )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HNGSNGBEES:NSE
Nippon India ETF Hang Seng BeE.. 0.00 (0.00%) N/A N/A N/A

ETFs Containing BETA

Symbol Name BETA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Beta Drugs Ltd. (BETA:NSE) Stock

Based on ratings from 1 analysts Beta Drugs Ltd.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for BETA:NSE is INR 1,600.00 over the next 12 months. The maximum analyst target price is INR 1600 while the minimum anlayst target price is INR 1600.

Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its overvalued.

The last closing price of BETA:NSE's stock was INR 1,197.80.

Unfortunately we do not currently have any market capitalization data for BETA:NSE's stock.

Based on targets from 1 analysts, the average taret price for BETA:NSE is projected at INR 1,600.00 over the next 12 months. This means that BETA:NSE's stock price may go up by +33.58% over the next 12 months.

We can't find any ETFs which contains Beta Drugs Ltd.'s stock.

Sorry, we do not have any data on the number of employees for Beta Drugs Ltd..

Sorry we do not have any infomation available on Beta Drugs Ltd.'s address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...